Effects of the components of hormone therapy on matrix metalloproteinases in breast-cancer cells: an in vitro study

被引：7
作者：
Abdallah, Maher A.
Abdullah, Huda I.
Kang, Steven
Taylor, Douglas D.
Nakajima, Steven T.
Gercel-Taylor, Cicek
机构：
[1] Univ Louisville, Sch Med, Dept Obstet Gynecol & Womens Hlth, Div Reprod Endocrinol, Louisville, KY 40202 USA
[2] New York Med Coll, Valhalla, NY USA
[3] Univ Louisville, Sch Med, Dept Obstet Gynecol & Womens Hlth, Div Gynecol Oncol, Louisville, KY 40202 USA
来源：
FERTILITY AND STERILITY | 2007年 / 87卷 / 04期
关键词：
D O I：
10.1016/j.fertnstert.2006.08.091
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
A combination of E and progestogens significantly increased matrix metalloproteinase (MMP)-2 in both T47D cells (E-2-medroxyprogesteroneacetate [MPA] and E-2-P) and MCF-7 cells (E-2-MPA, E-2-P, and equilin-MPA). All combinations resulted in higher MMP-9 levels in MCF-7 cells, but higher MMP-9 levels resulted only with equilin-norethinderone in T47D cells.
引用
收藏
页码：978 / 981
页数：4
相关论文
共 27 条
  • [1] Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial
    Anderson, GL
    Limacher, M
    Assaf, AR
    Bassford, T
    Beresford, SAA
    Black, H
    Bonds, D
    Brunner, R
    Brzyski, R
    Caan, B
    Chlebowski, R
    Curb, D
    Gass, M
    Hays, J
    Heiss, G
    Hendrix, S
    Howard, BV
    Hsia, J
    Hubbell, A
    Jackson, R
    Johnson, KC
    Judd, H
    Kotchen, JM
    Kuller, L
    LaCroix, AZ
    Lane, D
    Langer, RD
    Lasser, N
    Lewis, CE
    Manson, J
    Margolis, K
    Ockene, J
    O'Sullivan, MJ
    Phillips, L
    Prentice, RL
    Ritenbaugh, C
    Robbins, J
    Rossouw, JE
    Sarto, G
    Stefanick, ML
    Van Horn, L
    Wactawski-Wende, J
    Wallace, R
    Wassertheil-Smoller, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14): : 1701 - 1712
  • [2] Lower doses of oral estrogen and progestogens as treatment for postmenopausal women
    Archer, DF
    [J]. SEMINARS IN REPRODUCTIVE MEDICINE, 2005, 23 (02) : 188 - 195
  • [3] Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines
    Bachmeier, BE
    Albini, A
    Vené, R
    Benelli, R
    Noonan, D
    Weigert, C
    Weiler, C
    Lichtinghagen, R
    Jochum, M
    Nerlich, AG
    [J]. EXPERIMENTAL CELL RESEARCH, 2005, 305 (01) : 83 - 98
  • [4] Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies
    Bazzett, LB
    Magnus, M
    Taylor, DD
    Gercel-Taylor, C
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (02) : 435 - 442
  • [5] Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
  • [6] EXPRESSION OF ACTIVATED GELATINASE IN HUMAN INVASIVE BREAST-CARCINOMA
    BROWN, PD
    BLOXIDGE, RE
    ANDERSON, E
    HOWELL, A
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 1993, 11 (02) : 183 - 189
  • [7] Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations
    Coussens, LM
    Fingleton, B
    Matrisian, LM
    [J]. SCIENCE, 2002, 295 (5564) : 2387 - 2392
  • [8] Progestin suppresses matrix metalloproteinase production in endometrial cancer
    Di Nezza, LA
    Jobling, T
    Salamonsen, LA
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 89 (02) : 325 - 333
  • [9] Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways
    Katzenellenbogen, BS
    [J]. JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2000, 7 (01) : S33 - S37
  • [10] A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma
    Leppä, S
    Saarto, T
    Vehmanen, L
    Blomqvist, C
    Elomaa, I
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (03) : 1057 - 1063
123